Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Ashlyn Bartello

Physician Assistant Conyers, GA Physician Assistant

NPI 1306552526 CMS profile 11444114

1910 Highway 20 Se Ste 270, Conyers, GA 30013

Open in the dashboard

General payments

$2,201

110 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashlyn Bartello of Conyers, GA is reported in the CMS Open Payments database as having received $2,201 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,163 59
2024 General $550 27
2023 General $488 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashlyn Bartello
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashlyn Bartello were reported at $1,163. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashlyn Bartello Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $488 $167 $52–$557 $160
2024 $550 $178 $55–$600 $164
2025 $1,163 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Lilly USA, LLC $269 14 payments
  2. Otsuka America Pharmaceutical, Inc. $204 10 payments
  3. AbbVie, Inc. $174 8 payments
  4. Dexcom, Inc. $174 8 payments
  5. AstraZeneca Pharmaceuticals LP $157 9 payments
  6. Novo Nordisk Inc $156 9 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $125 6 payments
  8. Pfizer Inc. $112 5 payments
  9. Xeris Pharmaceuticals, Inc. $94 4 payments
  10. GlaxoSmithKline, LLC. $92 5 payments
  11. Other $644 32 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,201 110 payments
Products named General payments · program years 2023–2025
  1. REXULTI Psychiatry $204 10 payments
  2. Dexcom G6 Transmitter $174 8 payments
  3. MOUNJARO $127 7 payments
  4. NURTEC ODT $98 4 payments
  5. ELIQUIS $98 4 payments
  6. GVOKE HYPOPEN $94 4 payments
  7. REXULTI Psychiatry $90 4 payments
  8. FARXIGA $83 5 payments
  9. JARDIANCE $78 4 payments
  10. UBRELVY $65 3 payments
  11. Other $1,381 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

3,811

Median for Physician Assistant: 241

Drug cost

$360,939

Median for Physician Assistant: $4,110

Branded share of claims

22.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 70 $82,311
Mounjaro Tirzepatide Brand 61 $76,447
Ozempic Semaglutide Brand 43 $48,029
Trulicity Dulaglutide Brand 33 $30,857
Eliquis Apixaban Brand 20 $30,100
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $20,778
Farxiga Dapagliflozin Propanediol Brand 18 $15,265
Januvia Sitagliptin Phosphate Brand 11 $11,535
Albuterol Sulfate Hfa Albuterol Sulfate Brand 88 $4,177
Ondansetron Hcl Generic 40 $3,049

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$23,650

Of which drugs: $1,130

Medicare patients

164

Average age 75

Services billed

499

128 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Chronic kidney disease 40%
Diabetes 34%
Depression 24%
Ischemic heart disease 22%
Osteoporosis 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,054

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $76
$76 — —
VRAYLAR
  • AbbVie, Inc. $45
$45 — —
MOUNJARO
  • Lilly USA, LLC $42
$42 61 —
JARDIANCE
  • Lilly USA, LLC $23
  • Boehringer Ingelheim Pharmaceuticals, Inc. $16
$39 70 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $37
$37 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record